BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 33903940)

  • 1. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
    de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
    J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
    Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C11orf95-RELA, YAP1-MAMLD1, and YAP1-FAM118B Fusion Negative Anaplastic Ependymoma with Lipogenic Differentiation.
    Jha S; Mulgulwar PB; Sharma MC; Purkait S; Pattnaik A; Sable MN
    Neurol India; 2023; 71(5):1011-1014. PubMed ID: 37929446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
    Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
    J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
    Lötsch D; Kirchhofer D; Englinger B; Jiang L; Okonechnikov K; Senfter D; Laemmerer A; Gabler L; Pirker C; Donson AM; Bannauer P; Korbel P; Jaunecker CN; Hübner JM; Mayr L; Madlener S; Schmook MT; Ricken G; Maaß K; Grusch M; Holzmann K; Grasl-Kraupp B; Spiegl-Kreinecker S; Hsu J; Dorfer C; Rössler K; Azizi AA; Foreman NK; Peyrl A; Haberler C; Czech T; Slavc I; Filbin MG; Pajtler KW; Kool M; Berger W; Gojo J
    Acta Neuropathol; 2021 Aug; 142(2):339-360. PubMed ID: 34046693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ependymomas of the spinal region in adults: Clinical and pathological features and MYCN expression levels in spinal ependymomas and myxopapillary ependymomas.
    Topel G; Dirilenoğlu F; Sevin İE; Kahraman A
    Ann Diagn Pathol; 2024 Jun; 70():152299. PubMed ID: 38555652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.
    de Almeida Magalhães T; Alencastro Veiga Cruzeiro G; Ribeiro de Sousa G; Englinger B; Fernando Peinado Nagano L; Ancliffe M; Rodrigues da Silva K; Jiang L; Gojo J; Cherry Liu Y; Carline B; Kuchibhotla M; Pinto Saggioro F; Kazue Nagahashi Marie S; Mieko Oba-Shinjo S; Andres Yunes J; Gomes de Paula Queiroz R; Alberto Scrideli C; Endersby R; Filbin MG; Silva Borges K; Salic A; Gonzaga Tone L; Valera ET
    Neuro Oncol; 2023 Jan; 25(1):185-198. PubMed ID: 35640920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
    Träger M; Schweizer L; Pérez E; Schmid S; Hain EG; Dittmayer C; Onken J; Fukuoka K; Ichimura K; Schüller U; Dührsen L; Müther M; Paulus W; Thomas C; Gutt-Will M; Schucht P; Maragkou T; Schittenhelm J; Eckert F; Niyazi M; Fleischmann DF; Dorostkar MM; Feyer P; May SA; Moskopp D; Badakhshi H; Radke C; Walter J; Ehret F; Capper D; Kaul D
    Neuro Oncol; 2023 Jul; 25(7):1286-1298. PubMed ID: 36734226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ependymoma-like tumor with mesenchymal differentiation (ELTMD) with ZFTA:NCOA1 fusion: A diagnostic challenge.
    Dorwal P; White C; Goh AF; Kumar A; McEniery J; Walker R; Robertson T
    Neuropathology; 2024 Jun; 44(3):216-221. PubMed ID: 37931917
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hatanaka EA; Breunig JJ
    Front Oncol; 2024; 14():1360358. PubMed ID: 38469231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.
    de Sousa GR; Salomão KB; Nagano LFP; Riemondy KA; Chagas PS; Veronez LC; Saggioro FP; Marie SKN; Yunes JA; Cardinalli IA; Brandalise SR; de Paula Queiroz RG; Scrideli CA; Donson AM; Foreman NK; Tone LG; Valera ET
    Cancer Gene Ther; 2023 Aug; 30(8):1105-1113. PubMed ID: 37041276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging features to distinguish posterior fossa ependymoma subgroups.
    Leclerc T; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Puget S; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
    Eur Radiol; 2024 Mar; 34(3):1534-1544. PubMed ID: 37658900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
    Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.
    Hoffman LM; Donson AM; Nakachi I; Griesinger AM; Birks DK; Amani V; Hemenway MS; Liu AK; Wang M; Hankinson TC; Handler MH; Foreman NK
    Acta Neuropathol; 2014 May; 127(5):731-45. PubMed ID: 24240813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology.
    Gödicke S; Kresbach C; Ehlert M; Obrecht D; Altendorf L; Hack K; von Hoff K; Carén H; Melcher V; Kerl K; Englinger B; Filbin M; Pajtler KW; Gojo J; Pietsch T; Rutkowski S; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):23. PubMed ID: 38265527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.
    Pajtler KW; Mack SC; Ramaswamy V; Smith CA; Witt H; Smith A; Hansford JR; von Hoff K; Wright KD; Hwang E; Frappaz D; Kanemura Y; Massimino M; Faure-Conter C; Modena P; Tabori U; Warren KE; Holland EC; Ichimura K; Giangaspero F; Castel D; von Deimling A; Kool M; Dirks PB; Grundy RG; Foreman NK; Gajjar A; Korshunov A; Finlay J; Gilbertson RJ; Ellison DW; Aldape KD; Merchant TE; Bouffet E; Pfister SM; Taylor MD
    Acta Neuropathol; 2017 Jan; 133(1):5-12. PubMed ID: 27858204
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Whitehouse JP; Hii H; Mayoh C; Wong M; Ajuyah P; Barahona P; Cui L; Dholaria H; White CL; Buntine MK; Byrne J; Rodrigues da Silva K; Howlett M; Girard EJ; Tsoli M; Ziegler DS; Dyke JM; Lee S; Ekert PG; Cowley MJ; Gottardo NG; Endersby R
    Front Oncol; 2023; 13():1123492. PubMed ID: 36937401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
    Neyazi S; Yamazawa E; Hack K; Tanaka S; Nagae G; Kresbach C; Umeda T; Eckhardt A; Tatsuno K; Pohl L; Hana T; Bockmayr M; Kim P; Dorostkar MM; Takami T; Obrecht D; Takai K; Suwala AK; Komori T; Godbole S; Wefers AK; Otani R; Neumann JE; Higuchi F; Schweizer L; Nakanishi Y; Monoranu CM; Takami H; Engertsberger L; Yamada K; Ruf V; Nomura M; Mohme T; Mukasa A; Herms J; Takayanagi S; Mynarek M; Matsuura R; Lamszus K; Ishii K; Kluwe L; Imai H; von Deimling A; Koike T; Benesch M; Kushihara Y; Snuderl M; Nambu S; Frank S; Omura T; Hagel C; Kugasawa K; Mautner VF; Ichimura K; Rutkowski S; Aburatani H; Saito N; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):22. PubMed ID: 38265489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong OLIG2 expression in supratentorial ependymoma, ZFTA fusion-positive: A potential diagnostic pitfall.
    de Castro JVA; Kulikowski LD; Wolff BM; Natalino R; Carraro DM; Torrezan GT; Scapulatempo Neto C; Amancio CT; Canedo FSNA; Feher O; Costa FD
    Neuropathology; 2024 Apr; 44(2):167-172. PubMed ID: 37855183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Fully Automated Deep-Learning Model for Predicting the Molecular Subtypes of Posterior Fossa Ependymomas Using T2-Weighted Images.
    Cheng D; Zhuo Z; Du J; Weng J; Zhang C; Duan Y; Sun T; Wu M; Guo M; Hua T; Jin Y; Peng B; Li Z; Zhu M; Imami M; Bettegowda C; Sair H; Bai HX; Barkhof F; Liu X; Liu Y
    Clin Cancer Res; 2024 Jan; 30(1):150-158. PubMed ID: 37916978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.